Streetbeat News

Analyst Ratings

FOXA

Guggenheim analyst Michael Morris has maintained a Buy rating on Fox (NASDAQ:FOXA) and raised the price target from $44 to $45.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 5:04 pm

ZVRA

Analysts have varied opinions on Zevra Therapeutics (NASDAQ:ZVRA), with most being bullish. Recent price targets average $19.71, up from $18.17. Despite positive analyst sentiment, Zevra faces financial challenges, including declining revenue and high debt.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 5:01 pm

MOS

Analysts have mixed views on Mosaic (NYSE:MOS) with recent ratings showing a shift towards indifference. The average 12-month price target has decreased by 8.23% to $29.67. Analysts have adjusted their ratings and price targets, reflecting evolving market conditions and company performance. Mosaic, a major phosphate and potash producer, faces challenges with a revenue decline of 17.01% and a net margin of -5.73%. Despite these challenges, the company maintains a strong market presence with a market capitalization above industry average.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 5:01 pm

CF

CF Industries Holdings (NYSE:CF) has received mixed analyst ratings over the past three months, with a trend towards more bullish perspectives. Analysts have set a 12-month average price target of $86.58, reflecting a 2.86% increase from the previous target. Despite a recent revenue decline, CF Industries maintains strong profitability and financial health, though it carries a higher debt-to-equity ratio than industry averages.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 5:00 pm

REGN

RBC Capital analyst Brian Abrahams maintains an Outperform rating on Regeneron Pharmaceuticals but lowers the price target from $1282 to $1252.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 5:00 pm

FLS

Flowserve (NYSE:FLS) has received varied analyst ratings, with a majority being bullish. Recent price targets show an upward trend, with an average target of $58.14. Despite strong revenue growth, Flowserve faces challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 5:00 pm

MPLN

MultiPlan shares declined following Citigroup's decision to lower its price target from $17.2 to $10.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:52 pm

PFE

Recent options activity for Pfizer (NYSE:PFE) shows a mixed sentiment with a slight bearish tilt. Of 26 trades, 50% were bearish, and 46% bullish. The options activity suggests a focus on a price range between $18.0 and $35.0. Analysts have set a target price of $45.0, with a recent downgrade to 'Overweight'.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 4:45 pm

UBER

Uber Technologies' shares experienced increased trading volume following analyst Josh Brown's bullish comments on CNBC.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 4:40 pm

NEM

Recent options trading trends for Newmont (NYSE:NEM) show a bearish sentiment among large investors, with 68% of trades being bearish. Despite this, analysts have given positive ratings with price targets ranging from $58 to $65. The stock is currently trading at $55.65, up 2.14%, but may be approaching overbought levels.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 4:30 pm